Holen Sie sich die Stockscreener-App
5.70
5.36%
0.29
Handel nachbörslich:
5.70
Schlusskurs vom Vortag:
$5.41
Offen:
$5.53
24-Stunden-Volumen:
23.42M
Relative Volume:
0.88
Marktkapitalisierung:
$2.44B
Einnahmen:
$64.60M
Nettoeinkommen (Verlust:
$-377.75M
KGV:
-3.6774
EPS:
-1.55
Netto-Cashflow:
$-335.64M
1W Leistung:
+4.01%
1M Leistung:
+7.95%
6M Leistung:
-32.94%
1J Leistung:
-12.84%
1-Tages-Spanne:
$5.52
$5.82
1-Wochen-Bereich:
$5.20
$5.82
52-Wochen-Spanne:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Vergleichen Sie RXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.70 | 2.35B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Recursion Pharmaceuticals: Two Clinical Readouts In H2'25 (NASDAQ:RXRX) - Seeking Alpha
Recursion outlines $100M partnership inflows target by end of 2026 as cash runway extends through Q4 2027 - MSN
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - The Motley Fool
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down - MSN
Recursion Bets Big On AI-Driven Drug Discovery, But Losses Mount - Finimize
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating - MSN
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript - MSN
Why Recursion Pharmaceuticals Stock Tanked on Tuesday - Mitrade
Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week - 富途牛牛
Recursion Pharmaceuticals Reports Q2 Loss, Beats Revenue Estimates - AInvest
Broker Revenue Forecasts For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher - ca.finance.yahoo.com
Recursion Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Recursion Pharmaceuticals shares fall 1.99% premarket after reporting a wider Q2 loss. - AInvest
Recursion Pharmaceuticals: Q2 Earnings Snapshot - Stamford Advocate
Recursion Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Recursion (RXRX) Q2 Revenue Jumps 33% - AOL.com
Recursion Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks
Recursion Pharmaceuticals: Balancing AI Advancements with Financial Prudence Justifies Hold Rating - TipRanks
Recursion Pharmaceuticals and Biodexa: A High-Stakes Race in the FAP Market - AInvest
Recursion Pharmaceuticals: Strong Financial Position and Strategic Focus Justify Buy Rating - TipRanks
Recursion's Q2 2025 Earnings Call: Unpacking Key Contradictions in Strategy and Innovation - AInvest
Recursion Pharmaceuticals (RXRX): A Deep Dive into Platform-Driven Value Creation and Strategic Milestone Potential in 2025 - AInvest
Recursion Pharmaceuticals sets $100M partnership inflows target by 2026, extends cash runway to Q4 2027 - AInvest
Pharma Boom: RXRX Stocks Soar After Latest Innovation - timothysykes.com
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates - MSN
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates - Benzinga
Recursion Pharmaceuticals reports Q2 EPS (41c), consensus (35c) - TipRanks
Earnings call transcript: Recursion Pharmaceuticals Q2 2025 sees revenue beat - Investing.com
Recursion Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Up 50% in 3 Months, Is This Stock Still a Buy? - AOL.com
Recursion Pharmaceuticals Fiscal Q2 Loss Widens, Revenue Rises - MarketScreener
Recursion Pharmaceuticals shares rise 4.31% premarket after reporting revenue of $19.2 million, exceeding expectations. - AInvest
Why Recursion Pharmaceuticals Shares Are Gaining Momentum - TipRanks
Recursion Pharmaceuticals earnings missed by $0.06, revenue topped estimates - Investing.com Australia
RECURSION PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Recursion Reports Q2 2025 Business Updates and Financial Results - Quiver Quantitative
Earnings Flash (RXRX) Recursion Pharmaceuticals Inc Reports Q2 Revenue $19.2M, vs. FactSet Est of $15.4M - MarketScreener
Recursion Reports Q2 Financial Results, Deploys Advanced Models for Medicine Discovery. - AInvest
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards? - MSN
Recursion Pharmaceuticals Earnings Preview - 富途牛牛
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):